We use some essential cookies to make this website work.
We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.
We also use cookies set by other sites to help us deliver content from their services.
You have accepted additional cookies. You can change your cookie settings at any time.
You have rejected additional cookies. You can change your cookie settings at any time.
Departments, agencies and public bodies
News stories, speeches, letters and notices
Detailed guidance, regulations and rules
Reports, analysis and official statistics
Consultations and strategy
Data, Freedom of Information releases and corporate reports
Past and current clinical trials into therapeutic and antiviral treatments for COVID-19, how to take part, and which treatments have proven to be effective.
Find out about coronavirus (COVID-19) treatments available outside of hospital, including information on free prescriptions and lateral flow tests.
Treatment forms (T1 to T6) for use in connection with patients detained under the Mental Health Act 1983, who are in receipt of treatment for a mental disorder.
Tax and reporting rules for employers providing medical or dental treatment and insurance
Collection of documents relating to COVID-19 treatments.
How we evaluated pre-exposure prophylactic (preventative) treatments for COVID-19.
Help available and steps you should take if you have a medical emergency or are hospitalised abroad, including for planned treatment.
Section (4A.01 - 4A.31) last updated October 2023.
Read about talking therapies and counselling for mental health problems.
Visit the UK for medical treatment - check if you’re eligible and if you need a visa, what visa to apply for, what to do when you travel to the UK.
The National Treatment Agency for Substance Misuse (NTA) was established in 2001 to improve the availability, capacity and effectiveness of drug treatment. It became part of Public Health England in 2013.
DHSC publications relating to COVID-19 treatments and clinical trials.
The Medicines and Healthcare products Regulatory Agency (MHRA) has today (11 March 2024) approved the medicine quizartinib (Vanflyta) to be used alongside chemotherapy as first line treatment for adults who have acute myeloid leukaemia (AML).
Information for those who have been prescribed Paxlovid.
How to apply for a clinical trial including eligibility, phases, model IMPDs, costs and how to make changes to your application.
Don’t include personal or financial information like your National Insurance number or credit card details.
To help us improve GOV.UK, we’d like to know more about your visit today. We’ll send you a link to a feedback form. It will take only 2 minutes to fill in. Don’t worry we won’t send you spam or share your email address with anyone.